Paperpal Prime Logo

The Lancet Regional Health - Europe : Impact Factor & More

eISSN: 2666-7762pISSN: 2666-7762
JournalOpen Access

Key Metrics

CiteScore
5
Scite Index
0.87 5-Year SI
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on The Lancet Regional Health - Europe

The Lancet Regional Health - Europe Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • DOAJ DOAJ
  • SJR SJR
Overview
Publisher ELSEVIER
Language English
Frequency Monthly
Article Processing ChargesUSD 4000
Publication Time9
Editorial Review ProcessAnonymous peer review
General Details
LanguageEnglish
FrequencyMonthly
Publisher URLVisit website
Website URLVisit website
Publication Details
PlagiarismVisit website
Publication Time 9
Waiver PolicyVisit website
Editorial Review Detail
Editorial TeamVisit website
Review ProcessAnonymous peer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Copyright DetailsVisit website
License typeCC BY, CC BY-NC-ND
OA statementVisit website
View less

Planning to publish in The Lancet Regional Health - Europe ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in The Lancet Regional Health - Europe

Infectious diseases burden of health system collapse in Gaza and Lebanon: a call for action
  • 1 Oct 2026
  • The Lancet Regional Health - Europe
Outcomes, prognostic factors, and the role of intracranial pressure monitoring in severe community-acquired bacterial meningitis: a multicenter retrospective cohort study.
  • 1 Sep 2026
  • The Lancet regional health. Europe
Rebalancing innovation, affordability, and access for orphan drugs in the European Union.
  • 1 Sep 2026
  • The Lancet regional health. Europe
Whole genome sequencing in cerebral palsy: a UK paediatric pilot study.
  • 1 Sep 2026
  • The Lancet regional health. Europe
Endolymphatic duct blockage for Ménière's disease: a double-blind, randomised controlled trial.
  • 1 Sep 2026
  • The Lancet regional health. Europe
Prolonged CD38 targeting with felzartamab in antibody-mediated kidney transplant rejection: a biomarker-guided open-label phase 2 extension.
  • 1 Sep 2026
  • The Lancet regional health. Europe
Infectious diseases burden of health system collapse in Gaza and Lebanon: a call for action
  • 1 Oct 2026
  • The Lancet Regional Health - Europe
Outcomes, prognostic factors, and the role of intracranial pressure monitoring in severe community-acquired bacterial meningitis: a multicenter retrospective cohort study.
  • 1 Sep 2026
  • The Lancet regional health. Europe
Rebalancing innovation, affordability, and access for orphan drugs in the European Union.
  • 1 Sep 2026
  • The Lancet regional health. Europe
Whole genome sequencing in cerebral palsy: a UK paediatric pilot study.
  • 1 Sep 2026
  • The Lancet regional health. Europe
Endolymphatic duct blockage for Ménière's disease: a double-blind, randomised controlled trial.
  • 1 Sep 2026
  • The Lancet regional health. Europe
Prolonged CD38 targeting with felzartamab in antibody-mediated kidney transplant rejection: a biomarker-guided open-label phase 2 extension.
  • 1 Sep 2026
  • The Lancet regional health. Europe

FAQs on The Lancet Regional Health - Europe